Masahito Shimojo

Title: Masahito Shimojo: Innovator in Cancer Therapeutics

Introduction

Masahito Shimojo is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of cancer therapeutics, particularly in the development of innovative agents for treating small cell lung cancer.

Latest Patents

Masahito Shimojo holds a patent for a small cell lung cancer therapeutic agent containing oligonucleotide. This patent discloses an oligonucleotide or a pharmacologically acceptable salt thereof, which comprises at least one defined nucleoside structure. The oligonucleotide can bind to a human nSR100 gene and exhibits human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer and is complementary to a defined target region. Additionally, the patent describes an nSR100 gene expression inhibitor and a cancer therapeutic agent that includes the oligonucleotide or its pharmacologically acceptable salt. This cancer therapeutic agent is intended for the treatment of small cell lung cancer, prostate cancer, or breast cancer.

Career Highlights

Throughout his career, Masahito Shimojo has worked with esteemed institutions such as Osaka University and the National Institutes of Biomedical Innovation, Health and Nutrition. His work has focused on advancing cancer treatment methodologies and improving patient outcomes.

Collaborations

Masahito Shimojo has collaborated with notable colleagues, including Satoshi Obika and Yuya Kasahara. Their combined expertise has contributed to the development of innovative therapeutic solutions in the field of oncology.

Conclusion

Masahito Shimojo's work in cancer therapeutics exemplifies the impact of innovative research on medical science. His contributions continue to pave the way for advancements in the treatment of various cancers.